Vanda Pharmaceuticals (VNDA) Tops Q1 EPS by 2c, provides guidance
Tweet
Share
E-mail
Get Alerts VNDA Hot Sheet
Price: $5.09 +0.99%
Revenue Growth %: +24.1%
Financial Fact:
Income (loss) from operations: -653K
Today's EPS Names:
ANAB, ANIX, MNY, More
Revenue Growth %: +24.1%
Financial Fact:
Income (loss) from operations: -653K
Today's EPS Names:
ANAB, ANIX, MNY, More
Join SI Premium – FREE
Vanda Pharmaceuticals (NASDAQ: VNDA) reported Q1 EPS of $0.00, $0.02 better than the analyst estimate of ($0.02). Revenue for the quarter came in at $50.04 million versus the consensus estimate of $61.02 million.
GUIDANCE:
Vanda Pharmaceuticals sees FY2025 revenue of $210-250 million, versus the consensus of $222.9 million.
For earnings history and earnings-related data on Vanda Pharmaceuticals (VNDA) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Corning (GLW) files for up to $2B offering of common shares
- Boeing wins $13.4 billion contract modification from US military
- GMR Solutions to reprice $2.9B term loan, pay down $200M in debt
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
